/
FLGT
$20.53+$0.57 (+2.86%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$566.9M
28M shares
52-week range
$13.46 – $31.04
40% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-71.70
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21.4M | $32.5M | $421.7M | $992.6M | $619.0M | $289.2M | $283.5M | $322.7M |
| Cost of revenue | $10.7M | $14.1M | $89.8M | $215.5M | $252.1M | $184.8M | $176.3M | $191.8M |
| Gross profit | $10.7M | $18.4M | $331.9M | $777.1M | $366.9M | $104.5M | $107.2M | $130.9M |
| Gross margin | 49.9% | 56.6% | 78.7% | 78.3% | 59.3% | 36.1% | 37.8% | 40.6% |
| R&D | $5.5M | $6.5M | $11.6M | $24.2M | $28.9M | $41.4M | $48.8M | $53.9M |
| Operating income | −$5.1M | −$428.0K | $290.2M | $676.0M | $178.5M | −$195.5M | −$73.9M | −$91.1M |
| EBITDA | −$2.9M | $1.7M | $293.1M | $692.0M | $217.7M | −$147.5M | −$26.9M | −$45.8M |
| Net income | −$5.6M | −$411.0K | $214.3M | $507.4M | $143.4M | −$167.8M | −$42.7M | −$60.5M |
| Net margin | -26.3% | -1.3% | 50.8% | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% |
| EPS (diluted) | -0.25 | -0.02 | 8.91 | 16.26 | 4.63 | -5.63 | -1.41 | -1.97 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $352M | $-1.55 | $-1.55–$-1.55 | 1 |
| 2027 | $402M | $-1.15 | $-1.15–$-1.15 | 1 |
| 2028 | $435M | $-0.99 | $-0.99–$-0.99 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.61
Price
$20.53
Implied downside
-78%
Peer comparison
Fulgent Genetics, Inc. Common Stock
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
www.fulgentgenetics.com- Employees
- 1,315
- IPO / List date
- Sep 29, 2016
- HQ
- EL MONTE, CA
Held by traders on TradeandTell
No one on the platform currently holds FLGT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 18,000 | $286.2K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded FLGT yet.
